Leaflet TYPHIM VI solution for injection


Indicated for: prevention of typhoid fever

Route of administration: injectable

Substance: typhoid vaccine, purified polysaccharide vaccine (vaccine)

ATC: J07AP03 (Antiinfectives for systemic use | Bacterial vaccines | Typhoid vaccines)

The purified polysaccharide typhoid vaccine is used to prevent typhoid fever, a bacterial disease caused by Salmonella typhi. The vaccine contains a purified capsular polysaccharide (Vi antigen) that stimulates the immune system to produce antibodies against the bacteria, providing protection against infection.

The vaccine is administered intramuscularly, usually in a single dose, and is recommended for individuals traveling to endemic areas as well as those at increased risk of infection. The protection provided by the vaccine lasts approximately 2-3 years, and revaccination is necessary to maintain immunity.

Common side effects include pain at the injection site, mild fever, fatigue, and muscle aches. In rare cases, severe allergic reactions may occur.

The purified polysaccharide typhoid vaccine is an important preventive measure for reducing the incidence of typhoid fever, particularly in regions with poor sanitation and limited access to safe drinking water.

General data about TYPHIM VI

  • Substance: typhoid vaccine, purified polysaccharide vaccine
  • Date of last drug list: 01-05-2026
  • Commercial code: W43027001
  • Pharmaceutical form: solution for injection
  • Quantity: 1
  • Product type: original
  • Price: 138.24 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: SANOFI PASTEUR SA - FRANTA
  • Holder: SANOFI PASTEUR - FRANTA
  • Number: 1346/2008/01
  • Shelf life: 3 years

Pharmaceutical forms available for typhoid vaccine, purified polysaccharide vaccine